The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
polymerase Any of a class of enzymes which catalyze the synthesis of polymeric molecules, especially nucleic acid polymers, typically by encouraging the base pairing of free nucleotides with those of an existing complementary template strand. DNA polymerases and RNA polymerases are essential for DNA replication and transcription, respectively.
Organomercury chemistry refers to the study of organometallic compounds that contain mercury. Many organomercury compounds are highly toxic, but some are, or have once been, used in medicine, e.g., merbromin ("Mercurochrome") and the vaccine preservative thiomersal.
Seven people were killed in a Russian attack on the offices of Ukraine's largest printing house, located in Kharkiv. One person was killed in a separate attack in Zaporizhzhia Oblast. Russian-installed authorities in Crimea claimed that two people were killed in a Ukrainian missile attack in Simferopol Raion. The pro-Ukrainian partisan group Atesh claimed that the attack targeted a communications hub in Alushta, while other attacks were reported on a military antenna in Semydviria, Belbek airfield and in Yevpatoria. Ukraine claimed to have shot down a Russian Su-25 jet over the Donbas. Several sources questioned this claim, stating that the footage of the incident appeared to have been taken from a video game. Russia claimed to have shot down a drone over Tatarstan. Officials claimed that one person was killed in a drone strike in Belgorod Oblast. Norway pledged a $190 million military aid package to Ukraine that included support for air defense, naval capabilities, radar, anti-drone systems, and boats. Russia warned the UK that it could strike British targets "on Ukraine's territory and beyond its borders" if weapons it supplied to Ukraine are used against targets on Russian soil. The first group of Ukrainian pilots passed the US F-16 training program at Morris Air National Guard Base in Arizona and will undergo further training in Europe. Putin signed a decree allowing the assets of the United States, its citizens, and its companies to be confiscated and used for compensation for losses incurred by international sanctions.
=== Media preparation and washing units === The washing unit provides cleaning services for laboratory glassware and plasticware. It handles laundering of work clothing and decontamination of genetically modified organism (GMO) waste and hazardous laboratory waste. The media preparation unit prepares cultivation media and solutions for tissue culture. It produces bacteriological media and agar plates.
Sources: en.wikipedia.org
Brazil also fields the R3 Emergency Operation Ration (Portuguese: Ração Operacional de Emergência – R3), a 12-hour ration to be used in situations where cooked foods cannot be provided for all meals. The R3 ration is similar to the R2 and uses the same components, but contains less food. The bag is printed with the emblem of the Brazilian Army, "Emergency Ration R3 (12 hours)" (Portuguese: Ração de Emergência R3 (12 Horas)) and Menu information. Inside are 3 thin plastic bags: 2 meal bags and 1 accessory packet.
=== Filtration === The Celle engineer, Wilhelm Berkefeld, recognized the ability of diatomaceous earth to filter and developed tubular filters (known as filter candles) fired from diatomaceous earth. During the cholera epidemic in Hamburg in 1892, these Berkefeld filters were used successfully. One form of diatomaceous earth is used as a filter medium, especially for swimming pools. It has a high porosity because it is composed of microscopically small, hollow particles. Diatomaceous earth (sometimes referred to by trademarked brand names such as Celite) is used in chemistry as a filtration aid, to increase flow rate, and filter very fine particles that would otherwise pass through or clog filter paper. It is also used to filter water, particularly in the drinking water treatment process and in fish tanks, and other liquids, such as beer and wine. It can also filter syrups, sugar, and honey without removing or altering their color, taste, or nutritional properties.
Increase of cellular intake of certain substances, most prominently glucose in muscle and adipose tissue (about two-thirds of body cells) Increase of DNA replication and protein synthesis via control of amino acid uptake Modification of the activity of numerous enzymes. The actions of insulin (indirect and direct) on cells include:
== Contraindications == The US Food and Drug Administration (FDA) prescription label advises that bupropion should not be prescribed to individuals with epilepsy or other conditions that lower the seizure threshold, such as anorexia nervosa, bulimia nervosa, or withdrawal from benzodiazepines or alcohol. It should be avoided in individuals who are taking monoamine oxidase inhibitors (MAOIs). The label recommends that caution should be exercised when treating people with liver damage, severe kidney disease, and severe hypertension, and in children, adolescents, and young adults due to the increased risk of suicidal ideation.
Cooling Benchmarking Study CLASP's Global Research team embarked on the development of a series of benchmarking studies in 2010. The first analysis in the series, the Cooling Benchmarking Study, was carried out in partnership with Econoler, Navigant, Centro de Ensayos Innovación y Servicios (CEIS) and the American Council for an Energy Efficiency Economy (ACEEE), and provides an international comparison of energy efficiency performance and policy measures for room air conditioners used in the residential sector. The study, which was finalized in July 2011, delivers first-of-their-kind conversion formulas to compare seasonal performance metrics of room air conditioners across economies that use different test methods. These formulas enable countries and experts a means to compare the stringency of various S&L programs and to identify opportunities to adopt S&L best practices. Opportunities for Success and CO2 Savings from Appliance Energy Efficiency Harmonization The study, published in collaboration with Paul Waide of Navigant Consulting, Lloyd Harrington of Energy Efficiency Strategies, and Michael Scholand, conducts an extensive investigation of the energy efficiency standards and labeling programs in place in China, the European Union, India, Japan, and the US. It documents Minimum Energy Performance Requirements for 24 types of residential, commercial, and industrial appliances and equipment in these economies and identifies products with the greatest potential for global harmonization.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.